Læknablaðið - 15.08.1993, Qupperneq 14

222
LÆKNABLAÐIÐ
Hjartaverndar eru þakkaðar blóðfitumælingar
og starfsfólki göngudeildar Landspítalans
einnig. Höfundar þakka Maríu Henley fyrir
vélritun og frágang þessarar greinar.
HEIMILDIR
1. Illingworth DR. HMG CoA reducatase inhibitors.
Curr Opinion Lipid 1991; 2: 24-30.
2. Sigurðsson G, Þorsteinsson Þ. Lóvastatínmeðferð við
hækkun lituprótína í blóði. Læknablaðið 1988; 74:
353-8.
3. Reihner E, Rudeling M, Stahlberg D, et al. Influence
of pravaslatin, a specilic inhibitor of HMG CoA
reductase, on hepatic metabolism of cholesterol. N
Engl J Med 1990; 323: 224-8.
4. Friedewald WT, Levy RI, Frederickson DS.
Estimation of the concentration of low-density
lipoprotein cholesterol in plasma without use of the
preparative ultracentrifuge. Clin Chem 1972; 18: 499-
502.
5. Lipid Research Clinics Program. The lipid research
clinics coronary primary prevention trial results: 1.
reduction in incidence of coronary heart diséase.
JAMA 1984; 251: 351-64.
6. Frick MH, et al. Helsinki Heart Study: Primary
prevention trial with gemfibrosil in middle-aged men
with dyslipidemia. N Engl J Med 1987; 317: 1237-
45.
7. Hay JW, Wittcls EH, Gotto AM. An economic
evalution of Lovastatin for cholesterol lowering and
coronary artery disease reduction. Am J Cardiol 1991;
67: 789.
8. NIH consensus development conference statement,
lowering blood cholesterol to prevent heart disease.
Arteriosclerosis 1985; 5: 404-12.
9. Study Group, European Atherosclerosis Society. The
recognition and management of hyperlipidaemia in
adults: A policy statement of the European
Atherosclerosis Society. Eur Heart J 1988; 9: 571-
600.
10. Þorgeirsson G, Sigurðsson G, Sigurðsson JA, et al.
Meðferð við hárri blóðfitu. Læknablaðið 1991; 77:
59-60.
11. Sigfússon N, Sigvaldason H, Guðmundsdóttir
II, et al. Breytingar á tíðni kransæðastíflu og
kransæðadauðsfalla á íslandi. Tengsl við áhættuþætti
og mataræði. Læknablaðið 1991; 77: 49-58.
12. Þorgeirsson G, Davíðsson D, Sigvaldason H,
Sigfússon N. Ahælluþættir kransæðasjúkdóms
meðal karla og kvenna á Islandi. Niðurstöður úr
hóprannsókn Hjartavemdar 1967-1985. Læknablaðið
1992; 78: 267-76.
13. Sigurðsson G, Baldursdóttir Á, Guðnason V,
Sigurðsson G. Þcttni fituprótína í Islendingum.
Læknablaðið 1992; 78: 172-9.
14. Hunninghake DB. HMG CoA reductase inhibitors.
Curr Opinion Lipid 1992; 3: 22-8.
15. Superko HR, et al. Effectiveness of low-dose
colestipol therapy in patients with moderate
hypercholeslerolemia. Am J Cardiol 1992; 70: 135-
40.
16. Cobb MM, Teitelbaum HS, Breslow JL. Lovastatin
efficacy in reducing low-density lipoprotein
cholesterol levels on high-vs low-fat diets. JAMA
1991; 265: 997-1001.
17. Steingrímsdóttir L, Sigurðsson G. Matarráðgjöf við
hækkuðu semm kólesteróli. Læknablaðið 1983; 69:
126-8.
18. Kristjansson S, Kjartansdottir Th, Johannsson M,
Kristinsson J, Sigurdsson G. Pravastatin monotherapy
in elderly primary moderate hypercholesterolaemic
and middle aged normocholesterolaemic volunteers -
pharmacokinetic evaluation. (Bíður birtingar.)
19. Scott WA. Hydrophilicity and the differential
pharmacology of pravastatin. Lipid management:
Pravastatin and the Differential Pharmacology of
HMG-CoA Reductase Inhibitor. Round Table Series,
No 16. London 1989; 16: 17-26.